BRIEF published on 06/15/2026 at 19:35, 3 months 7 days ago Oxurion: Exagis adopted by Pierre Fabre Biopharmaceutical Clinical Data Oxurion Exaggerate Pierre Fabre
BRIEF published on 06/15/2026 at 19:35, 3 months 7 days ago Oxurion's Exagis Platform Gains Major Market Validation with Pierre Fabre Laboratories Data Management Pharmaceutical Oxurion Pierre Fabre Exagis Platform
PRESS RELEASE published on 06/15/2026 at 19:30, 3 months 7 days ago Major market validation: Pierre Fabre Laboratories uses Oxurion's Exagis Platform Oxurion NV announces Pierre Fabre Laboratories utilizing Exagis clinical data management platform by Axiodis CRO, enhancing efficiency and compliance. Exagis adapts to various study configurations Oxurion NV Clinical Data Management Axiodis CRO Exagis Pierre Fabre Laboratories
BRIEF published on 06/10/2026 at 18:05, 3 months 12 days ago Oxurion receives a transparency notification from Atlas Special Opportunities II LLC Shares Transparency Euronext Brussels Oxurion Atlas Special Opportunities II LLC
BRIEF published on 06/10/2026 at 18:05, 3 months 12 days ago Oxurion Receives Notification on Shareholding Change Shares Transparency Notification Belgium Atlas Special Opportunities Oxurion
PRESS RELEASE published on 06/10/2026 at 18:00, 3 months 12 days ago Oxurion Receives Transparency Notification from Atlas Special Opportunities II LLC Oxurion NV received a transparency notification from Atlas Special Opportunities II, LLC regarding shareholding crossing the threshold. Oxurion is a technology-enabled clinical research company Clinical Research Transparency Notification Shareholding Oxurion NV Atlas Special Opportunities II, LLC
BRIEF published on 06/08/2026 at 21:05, 3 months 14 days ago Oxurion announces its software strategy with Exagis Growth Strategy Clinical Research Software Oxurion Exaggerate
BRIEF published on 06/08/2026 at 21:05, 3 months 14 days ago Oxurion Unveils Software-Driven Growth Strategy with Exagis Oxurion Clinical Data Management Exagis Software Strategy EClinical Platform
PRESS RELEASE published on 06/08/2026 at 21:00, 3 months 14 days ago Oxurion launches a software-driven growth strategy with Exagis Oxurion NV announces the software-driven growth strategy launch centered on Exagis, its proprietary clinical research platform. The platform evolves into a broad CDMS commercially serving clinical development market Oxurion NV Exagis Clinical Research Platform Software-driven Growth Strategy CDMS
BRIEF published on 06/03/2026 at 18:05, 3 months 19 days ago Oxurion Approves Agenda at Annual Shareholders' Meeting Forward-looking Statements Shareholders' Meeting Oxurion NV Leuven Agenda Approval
Published on 09/22/2026 at 17:00, 4 hours 25 minutes ago Leggett Dynamics Expands Asia Pacific Headquarters
Published on 09/22/2026 at 16:30, 4 hours 55 minutes ago Formation Metals Intersects 0.98 g/t Au over 95.6 Metres Starting 7 Metres Below Surface, Including 3.14 g/t Au over the First 10 Metres, Extending the A-Zone Up to 50 Metres North at N2
Published on 09/22/2026 at 15:25, 6 hours ago Aztec Minerals Announces Closing of Upsized C$6.4 Million Bought Deal Private Placement Including Concurrent Exercise of Underwriter's Option
Published on 09/22/2026 at 15:20, 6 hours 5 minutes ago MicroVision Introduces Advanced Photonics Technology for Next-Generation AI Data Center Scale-Up Architecture
Published on 09/22/2026 at 19:40, 1 hour 44 minutes ago EQS-Adhoc: Pyrum Innovations AG: Revision of the Forecast for the Financial Year 2026
Published on 09/22/2026 at 19:00, 2 hours 25 minutes ago LLB focuses on its "elevate" strategy for growth, excellence and resilience
Published on 09/22/2026 at 18:30, 2 hours 54 minutes ago Avolta partners with Hawaii’s Department of Transportation to expand airport dining at three airports
Published on 09/22/2026 at 17:45, 3 hours 40 minutes ago Carvolix submits 510(k) for TAVIPILOT Robot, advancing toward US commercial launch of Its Integrated TAVIPILOT Platform.
Published on 09/22/2026 at 17:40, 3 hours 45 minutes ago VALBIOTIS SA: Valbiotis announces positive results from the Cardio-Liver clinical study - Commercial launch of ValbiotisPRO® Foie on September 23
Published on 09/22/2026 at 18:00, 3 hours 25 minutes ago Consolidated results for the first half of 2026 EBITDA : 60,5 M€
Published on 09/22/2026 at 17:45, 3 hours 40 minutes ago Imerys-09-2026-information-share-capital-and-voting-rights-as-of-31-August-2026
Published on 09/21/2026 at 18:19, 1 day 3 hours ago Reporting on share buyback transactions carried out between September 14 and September 18, 2026
Published on 09/21/2026 at 18:01, 1 day 3 hours ago Partnership agreement signed between Manitou Group and HD Construction Equipment
